Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Unit of Cardiology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
Am J Nephrol. 2022;53(7):516-525. doi: 10.1159/000524889. Epub 2022 Jun 10.
Using data from the ertugliflozin cardiovascular outcomes trial in patients with type 2 diabetes mellitus (VERTIS CV; NCT01986881), associations between the initial estimated glomerular filtration rate (eGFR) "dip" with eGFR slope, glucosuria/natriuresis-related measures, and safety were investigated.
Patients were categorized into tertiles based on change in eGFR at week 6: >+1.00 mL/min/1.73 m2 (tertile 1), >-5.99 and ≤+1.00 (tertile 2), and ≤-6.00 (tertile 3). eGFR slope after week 6 and week 18 was assessed by tertile. Glucosuria/natriuresis-related measures were also determined. Adverse events (AEs) were analyzed in the acute (baseline-week 6) and chronic periods (week 6-30 days after last dose of trial medication).
In the ertugliflozin group, chronic eGFR slopes (95% CI, mL/min/1.73 m2/year; weeks 6-156) were -0.76 (-1.03, -0.50), -0.29 (-0.51, -0.07), and -0.05 (-0.26, 0.17) in tertiles 1, 2, and 3, respectively (p value <0.001), and approximately -1.5 mL/min/1.73 m2/year across tertiles in the placebo group (p value = 0.79). At week 18, least squares mean (LSM) changes from baseline in glycated hemoglobin (%) were -0.77, -0.71, and -0.67 in tertiles 1, 2, and 3, respectively, in the ertugliflozin group; a similar tertile-associated trend was observed for uric acid. At week 18, LSM changes from baseline in hematocrit (%) were 2.07, 2.33, and 2.55 in tertiles 1, 2, and 3, respectively, in the ertugliflozin group; similar tertile-associated trends were observed for blood pressure. All pinteraction values were <0.0001 for glucosuria- and natriuresis-related measures. Kidney-related AEs were reported more frequently in tertiles 3 and 2 in the chronic period for both placebo- and ertugliflozin-treated groups. In both periods and in all tertiles, incidences of AEs did not differ between placebo- and ertugliflozin-treated groups.
With ertugliflozin, the tertile with the largest initial dip in eGFR had a slower rate of chronic eGFR decline. Initial eGFR changes were associated with changes in both glucosuria- and natriuresis-related measures.
本研究使用来自患有 2 型糖尿病(VERTIS CV;NCT01986881)患者的恩格列净心血管结局试验的数据,探讨了初始估算肾小球滤过率(eGFR)“下降”与 eGFR 斜率、葡萄糖尿症/利钠相关指标以及安全性之间的关系。
根据第 6 周时 eGFR 的变化,患者被分为 3 个三分位组:>+1.00 mL/min/1.73 m2(三分位 1)、>+5.99 和≤+1.00(三分位 2)和≤-6.00(三分位 3)。第 6 周后和第 18 周通过三分位评估 eGFR 斜率。还确定了葡萄糖尿症/利钠相关指标。分析了急性(基线-第 6 周)和慢性(第 6 周-试验药物末次给药后 30 天)期间的不良事件(AE)。
在恩格列净组中,慢性 eGFR 斜率(95%CI,mL/min/1.73 m2/年;第 6-156 周)分别为-0.76(-1.03,-0.50)、-0.29(-0.51,-0.07)和-0.05(-0.26,0.17)在三分位 1、2 和 3 中(p 值<0.001),而在安慰剂组中,整个三分位的平均 eGFR 变化约为-1.5 mL/min/1.73 m2/年(p 值=0.79)。第 18 周时,恩格列净组的糖化血红蛋白(%)从基线的最小二乘均值(LSM)变化分别为三分位 1、2 和 3 中的-0.77、-0.71 和-0.67;尿酸也观察到类似的三分位相关趋势。第 18 周时,恩格列净组的红细胞压积(%)从基线的 LSM 变化分别为三分位 1、2 和 3 中的 2.07、2.33 和 2.55;血压也观察到类似的三分位相关趋势。所有葡萄糖尿症和利钠相关指标的 p 值均<0.0001。在慢性期,安慰剂和恩格列净治疗组的第 3 和第 2 三分位报告的肾脏相关 AE 更为频繁。在两个时期和所有三分位中,安慰剂和恩格列净治疗组的 AE 发生率没有差异。
在恩格列净治疗中,初始 eGFR 下降最大的三分位患者慢性 eGFR 下降速度较慢。初始 eGFR 变化与葡萄糖尿症和利钠相关指标的变化有关。